1 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 24744988 | Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? | 2014 | 1 |